11.5 USD
-0.85 (-6.88%)
Taking everything into account, INKT scores 1 out of 10 in our fundamental rating. INKT was compared to 535 industry peers in the Biotechnology industry. INKT has a bad profitability rating. Also its financial health evaluation is rather negative. INKT is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year INKT has reported negative net income.
INKT had a negative operating cash flow in the past year.
INKT had negative earnings in each of the past 5 years.
In the past 5 years INKT always reported negative operating cash flow.
1.2 Ratios
INKT has a worse Return On Assets (-82.57%) than 69.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -82.57% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-232.92%
ROA(5y)-574.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for INKT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
INKT has more shares outstanding than it did 1 year ago.
INKT has more shares outstanding than it did 5 years ago.
INKT has a worse debt/assets ratio than last year.
2.2 Solvency
INKT has an Altman-Z score of -15.93. This is a bad value and indicates that INKT is not financially healthy and even has some risk of bankruptcy.
INKT's Altman-Z score of -15.93 is on the low side compared to the rest of the industry. INKT is outperformed by 81.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -15.93 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
INKT has a Current Ratio of 1.08. This is a normal value and indicates that INKT is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.08, INKT is not doing good in the industry: 87.29% of the companies in the same industry are doing better.
A Quick Ratio of 1.08 indicates that INKT should not have too much problems paying its short term obligations.
The Quick ratio of INKT (1.08) is worse than 86.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.08 | ||
| Quick Ratio | 1.08 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 22.31% over the past year.
EPS 1Y (TTM)22.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 6.53% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y43.59%
EPS Next 2Y21.91%
EPS Next 3Y11.84%
EPS Next 5Y6.53%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
INKT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INKT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.91%
EPS Next 3Y11.84%
5. Dividend
5.1 Amount
No dividends for INKT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:INKT (12/5/2025, 8:00:01 PM)
11.5
-0.85 (-6.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners1.95%
Inst Owner Change47.41%
Ins Owners7.27%
Ins Owner Change0.15%
Market Cap53.94M
Revenue(TTM)N/A
Net Income(TTM)-12.36M
Analysts82.5
Price Target39.78 (245.91%)
Short Float %1.99%
Short Ratio1.21
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-32.32%
Min EPS beat(2)-90.1%
Max EPS beat(2)25.47%
EPS beat(4)1
Avg EPS beat(4)-24.68%
Min EPS beat(4)-90.1%
Max EPS beat(4)25.47%
EPS beat(8)4
Avg EPS beat(8)-0.16%
EPS beat(12)7
Avg EPS beat(12)4.27%
EPS beat(16)10
Avg EPS beat(16)9.09%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)7.34%
EPS NQ rev (3m)7.34%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.03
EYN/A
EPS(NY)-3.39
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.19
OCFYN/A
SpS0
BVpS-2.88
TBVpS-2.88
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -82.57% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-232.92%
ROA(5y)-574.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.08 | ||
| Quick Ratio | 1.08 | ||
| Altman-Z | -15.93 |
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)185.6%
Cap/Depr(5y)359.7%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30%
EPS Next Y43.59%
EPS Next 2Y21.91%
EPS Next 3Y11.84%
EPS Next 5Y6.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y65.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.45%
OCF growth 3YN/A
OCF growth 5YN/A
MINK THERAPEUTICS INC / INKT FAQ
Can you provide the ChartMill fundamental rating for MINK THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 0 / 10 to INKT.
Can you provide the valuation status for MINK THERAPEUTICS INC?
ChartMill assigns a valuation rating of 0 / 10 to MINK THERAPEUTICS INC (INKT). This can be considered as Overvalued.
Can you provide the profitability details for MINK THERAPEUTICS INC?
MINK THERAPEUTICS INC (INKT) has a profitability rating of 0 / 10.